Unlocking the full potential of therapeutic fusion proteins: R&D insights to help you get ahead

According to Yingzhu Li, Ph.D., Information Scientist and a contributing author on this blog post, organizations seeking innovative initiatives to accelerate the delivery of drugs to patients must stay abreast of the rapid developments in this area. CAS has collaborated with the National Science Library, Chinese Academy of Sciences (NSL) to produce a whitepaper on therapeutic proteins that's designed to give you the complete picture of the therapeutic fusion protein landscape and help you to identify the most promising opportunities. Here we've provided some key highlights from this useful resource, and how these insights could help your business gain the competitive advantage.

Gene and cell therapy: The R&D and market insights you need to get a competitive edge

Gene and cell therapies are now providing patients with treatments for many traditionally incurable diseases. These clinical successes are likely to be just the tip of the iceberg—the full promise of this field is yet to be realized. Pharmaceutical companies are therefore investing heavily in R&D to develop new products, with a surge of gene and cell therapy agents now entering early development.

Global vaccine trends: R&D and market insights driving new opportunities

Vaccines save millions of lives each year. By providing large-scale protection against serious diseases, vaccination programs proved to be one of the greatest public health achievements of the 20th century. Thanks to the advent of recombinant DNA technology and advanced multivalent vaccines, coupled with the ground-breaking innovation of cancer vaccines, the scope of vaccines continues to expand.

Top 5 COVID-19 vaccine questions answered

CAS launches new brand reflecting strategic evolution to empower smarter science

CAS launched a new brand reflecting the broadening scope of its solutions and capabilities critical to advancing scientific discovery. This new brand mirrors an on-going evolution to enable new and smarter uses of scientific information as a partner to R&D leaders pursuing more efficient, collaborative, and customized innovation models.

CAS Common Chemistry™ expands collection of publicly available chemical information

CAS has expanded the open access Common Chemistry resource to nearly 500,000 substances from CAS REGISTRY®. The collection represents substances commonly found in consumer products, regulatory lists, and introductory chemistry curricula.

New AI-Enabled Virtual Screening Tool Identifies Most Promising Approved Drugs for Success in Treating COVID-19

WorldQuant Predictive (WQP) and CAS have partnered to develop a groundbreaking methodology that can save time and lives by helping researchers rapidly prioritize the most promising drug candidates to treat COVID-19 and other critical diseases.

Scilligence Partners with CAS to Optimize R&D Informatics Workflows with Scientist-Curated Data

Scilligence, a provider of web-based informatics solutions for R&D, has partnered with CAS to enable direct access to CAS scientific content through the Scilligence informatics platform. This partnership builds on a previous collaboration by streamlining additional workflow scenarios. Users can now access CAS REGISTRY® data directly from Scilligence ELN and Scilligence Inventory.

MoA Technology integrates CAS chemical substance data into novel herbicide R&D workflow

CAS and MoA Technology, an innovator in herbicide R&D, announce an agreement to embed chemical substance data from the CAS REGISTRY®, as well as related reference and property information, directly into MoA’s R&D workflow via an application programming interface (API).